Therefore, unlike prior reviews that broadly surveyed all PCa imaging agents, this work is distinct in its exclusive focus on PSMA-negative and treatment-resistant disease phenotypes, for which alternative PET tracers are critically needed. This evidence concerns the gene FOLH1 and posterior cortical atrophy.